Introduction
============

While complement protein deficiencies are associated with severe and recurrent pulmonary infections, excessive complement activation plays a role in the pathogenesis of lung injury. We hypothesized that inhibition of the complement system by repetitive treatment with nebulized plasma-derived human C1-esterase inhibitor (C1-INH) reduces pulmonary complement activation and subsequently attenuates lung injury and lung inflammation in a model of severe *Streptococcus pneumoniae*pneumonia.

Methods
=======

Thirty-two male rats were intratracheally challenged with *S. pneumoniae*to induce pneumonia. Rats were repeatedly exposed to nebulized C1-INH or saline, 30 minutes before induction of pneumonia and every 6 hours thereafter. Rats were sacrificed 20 or 40 hours after inoculation to investigate early and late effects. BALF and lung tissue were obtained for measuring levels of complement activation (C4b/c in BALF), lung injury (total protein levels in BALF), and inflammation (IL-6 levels in lung tissue).

Results
=======

Pneumonia was characterized by bilateral macroscopic infiltrates, bacterial outgrowth in the lung and clinical signs of illness. Pneumonia was associated with pulmonary complement activation. In rats treated with nebulized C1-INH, a functional fraction of C1-INH was detectable in BALF. However, C1-INH treatment did not affect pulmonary complement activation (Figure [1A](#F1){ref-type="fig"}), lung injury (Figure [1B](#F1){ref-type="fig"}) or inflammation (Figure [1C](#F1){ref-type="fig"}).
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Conclusion
==========

Severe *S. pneumoniae*pneumonia is associated with pulmonary complement activation in rats. Nebulized C1-INH treatment, in an attempt to reduce pulmonary complement activation, neither affects pulmonary complement activation or lung injury and inflammation.
